PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20626385-2	2010	In this study, we examined the effect of CP-690,550 on IL-2-mediated Jak/STAT5 phosphorylation by CD4(+)CD25(bright)FoxP3(+)CD127(-/low) T cells (Treg) and CD4(+)CD25(neg) effector T cells (Teff) in kidney transplant (KTx) patients.	tofacitinib	41-47	signal transducer and activator of transcription 5A	Homo sapiens	73-78	
22705984-6	2012	Moreover, treatment of both JAK3-mutant and wild-type NKTCL cell lines with a novel pan-JAK inhibitor, CP-690550, resulted in dose-dependent reduction of phosphorylated STAT5, reduced cell viability, and increased apoptosis.	tofacitinib	103-112	signal transducer and activator of transcription 5A	Homo sapiens	169-174	
22960764-3	2012	METHODS: After whole-blood activation with the gamma(c) cytokines IL-2, IL-7, and IL-15, STAT5 phosphorylation was determined in T cells of de novo kidney transplantation patients treated with tofacitinib/basiliximab (n=5), calcineurin inhibitor (CNI) (cyclosporine A)/basiliximab (n=4) or CNI (tacrolimus)-based immunosuppression (n=6).	tofacitinib	193-204	signal transducer and activator of transcription 5A	Homo sapiens	89-94	
22960764-6	2012	In kidney transplantation patients, 7 days after starting tofacitinib/basiliximab treatment, cytokine-induced P-STAT5 was inhibited in CD4(+) T cells (92% for IL-2 activation, 60% for IL-7, and 75% for IL-15), which persisted for the 2-month study period.	tofacitinib	58-69	signal transducer and activator of transcription 5A	Homo sapiens	112-117	
22960764-10	2012	CONCLUSIONS: Tofacitinib therapy strongly inhibits gamma(c) cytokine-induced JAK/STAT5 activation, whereas basiliximab suppresses IL-2-stimulated activation only.	tofacitinib	13-24	signal transducer and activator of transcription 5A	Homo sapiens	81-86	
21106989-5	2011	Furthermore, CP-690,550 inhibited STAT5 phosphorylation in isolated ATL T cells ex vivo.	tofacitinib	13-19	signal transducer and activator of transcription 5A	Homo sapiens	34-39	
20626385-3	2010	Phosphospecific flow cytometry was used to study the effect of CP-690,550 on IL-2-induced intracellular STAT5-phosphorylation.	tofacitinib	63-69	signal transducer and activator of transcription 5A	Homo sapiens	104-109	
20626385-5	2010	In the presence of 100 ng/mL CP-690,550, a clinically relevant exposure, IL-2-induced P-STAT5 was partially inhibited in CD4(+)CD25(bright)Treg (% inhibition; 51%), while almost completely blocked in Teff (%inhibition; 84%, p = 0.03).	tofacitinib	29-35	signal transducer and activator of transcription 5A	Homo sapiens	86-93	
34630419-11	2021	Constitutive STAT1, STAT3, STAT4 and STAT5 phosphorylation in monocytes and/or T cells was also downregulated by tofacitinib.	tofacitinib	113-124	signal transducer and activator of transcription 5A	Homo sapiens	37-42	
19855246-4	2009	: As part of a phase 1 clinical trial, we investigated the effect of CP-690,550 after 29 days of 30 mg twice daily treatment at the cellular level in eight kidney transplant patients by studying ex vivo phosphorylation of STAT5 (P-STAT5), the key substrate of JAK3.	tofacitinib	69-75	signal transducer and activator of transcription 5A	Homo sapiens	229-236	
19855246-8	2009	At the functional level, the inhibitory effect of CP-690,550 was confirmed by determining the expression of several STAT5 targets genes.	tofacitinib	50-56	signal transducer and activator of transcription 5A	Homo sapiens	116-121	
19855246-10	2009	: Analysis of P-STAT5 may, therefore, be used to determine the immunomodulatory effect of CP-690,550 at the cellular level in transplant patients.	tofacitinib	90-96	signal transducer and activator of transcription 5A	Homo sapiens	14-21	
32539713-6	2020	Whereas compared with baricitinib or upadacitinib, the inhibitory effects of tofacitinib on the GM-CSF-induced JAK2/STAT5 phosphorylation were weak at lower concentrations (<= 100 nM).	tofacitinib	77-88	signal transducer and activator of transcription 5A	Homo sapiens	116-121	
32539713-5	2020	RESULTS: Treatment with JAKi (tofacitinib, baricitinib, upadacitinib) prevented GM-CSF-induced JAK2/STAT5 phosphorylation at higher concentrations (400 nM) in THP-1 cells.	tofacitinib	30-41	signal transducer and activator of transcription 5A	Homo sapiens	100-105	
27732937-6	2016	Treatment of these cell lines with tofacitinib reduced the levels of phospho-STAT5, suppressed proliferation, induced G1 cell-cycle arrest and decreased EBV LMP1 and EBNA1 expression.	tofacitinib	35-46	signal transducer and activator of transcription 5A	Homo sapiens	77-82	
31545408-6	2019	JAK3-selective inhibitor tofacitinib abrogated the phosphorylation of downstream signalling molecule STAT5, supressed cell growth, induced cell apoptosis and arrested the cell cycle at the G1/S phase in ITK-SYK+ Jurkat cells.	tofacitinib	25-36	signal transducer and activator of transcription 5A	Homo sapiens	101-106